Efficacy and Safety of Regorafenib with or without PD-1 Inhibitors as Second-Line Therapy for Advanced Hepatocellular Carcinoma in Real-World Clinical Practice
DOI: https://doi.org/10.2147/OTT.S383685
IF: 4
2022-10-01
OncoTargets and Therapy
Abstract:Kan Liu, 1, 2, &ast Jianbing Wu, 1, 2, &ast Yongkang Xu, 1, 2 Dan Li, 1, 2 Shenlang Huang, 1, 2 Ye Mao 1, 2 1 Department of Digestive Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, People's Republic of China; 2 Jiangxi Key Laboratory of Clinical and Translational Cancer Research, Nanchang, People's Republic of China &astThese authors contributed equally to this work Correspondence: Ye Mao, Email Background: Regorafenib is the first oral targeted drug as a second-line agent in patients with advanced hepatocellular carcinoma (HCC) who progressed on sorafenib treatment. Recently, several studies demonstrated that the combination of regorafenib and PD-1 inhibitors showed a synergistic effect. Our study aimed to evaluate the efficacy of regorafenib with PD-1 inhibitors (RP) and regorafenib alone (R) as second-line treatment for advanced HCC. Methods: From October 2018 to January 2022, our retrospective study evaluated advanced HCC patients who received regorafenib with PD-1 inhibitors or regorafenib alone as a second-line treatment at the Second Affiliated Hospital of Nanchang University, China. The efficacy and safety were compared between RP and R groups. Results: In total, 78 patients were enrolled in our study and were separated into two groups – RP group (48) and R group (30) – according to the criteria. The ORR of RP group and R group was 18.8% and 10%, respectively, and the DCR was 66.7% and 43.3%, respectively. The RP group had a longer mPFS (5.9 months vs 3.0 months, P < 0.001) and mOS (12.9 months vs 10.3 months, P =0.010) than the R group. Regorafenib monotherapy is an independent prognostic factor for OS and PFS. In OS, subgroup analysis showed that patients with AFP ≥ 400ng/mL, BCLC C stage and extrahepatic metastasis may benefit from RP, while in PFS, subgroup analysis showed that patients with BCLC C stage, AFP ≥ 400ng/mL, extrahepatic metastasis, ALBI ≥-2.60 and first-line treatment of sorafenib may benefit from RP. The incidence of grade 3/4 adverse reaction in the two groups was 22.9% and 23.3%, respectively, with no significant statistically difference ( P =0.966). Conclusion: In the second-line therapy of advanced HCC, compared to regorafenib alone, the combination of regorafenib and PD-1 inhibitors showed promising efficacy and tolerable drug toxicity. Keywords: hepatocellular carcinoma, second-line therapy, immunotherapy, regorafenib, PD-1 inhibitor HCC, the primary tumor of the liver, accounting for 75–85% of primary liver tumors, is the fifth most common cause of cancer worldwide and the fourth leading cause of cancer-related death worldwide. 1 The onset of HCC is insidious, and it is commonly diagnosed as locally advanced or distant metastases, which cannot be treated with surgery. The prognosis is poor, and the five-year survival rate is less than 20%. 2,3 Currently, the systemic first-line therapy of advanced HCC is mainly atezolizumab plus bevacizumab (A+T), sorafenib and lenvatinib, 4 and sintilimab plus bevacizumab analogs and Donafinib are also approved as first-line therapy in China. 5,6 When the patient's first-line therapy fails or cannot be tolerated, regorafenib, cabozantinib, ramucirumab, pembrolizumab and nivolumab are available as second-line therapy options. 4 However, the efficacy of second-line targeted therapy for advanced HCC patients was unmet. 7–10 The overall efficacy of immune checkpoint inhibitors has also not achieved very satisfactory results. 11–13 Yasuda et al found that the combination of anti-VEGFR2 and anti-PD-1 antibody could enhance the production of interferon-γ, tumor necrosis factor-α and granzyme B, thus enhancing the immune response of tumor mice. 14 Researches have indicated that anti-angiogenesis targeted treatment can reverse the immunosuppressive state of tumor microenvironment, normalize vascular permeability and immune environment, improve the immune response rate of immunosuppressants and reduce tumor drug resistance. 15,16 There is no standard combination regimen in the second-line therapy of HCC, and regorafenib may be the best choice. Regorafenib is a small molecular multi-target tyrosine kinase inhibitor that inhibits rapidly accelerated fibrosarcoma 1(RAF-1), B-RAF, B-RAFV600E (B-RAF mutants), VEGFR1, 2 and 3, carcinogenic protein kit and RET, angiopoietin 1 receptor (TIE2), platelet-derived growth factor receptor (PDGFR), fibroblast growth receptor (FGFRs) 1 and 2. 17–19 The RESORCE is a clinical trial of regorafenib as se -Abstract Truncated-
oncology,biotechnology & applied microbiology